Electromed prices 1,700,000 shares of initial public offering

NewsGuard 100/100 Score

Electromed, Inc. (Nasdaq:ELMD), which is a leader in developing innovative airway clearance therapy products for use by patients with compromised pulmonary function, today announced pricing of its initial public offering of 1,700,000 shares of common stock at a price of $4.00 per share, before underwriting discounts and commissions.

The offering is expected to close on August 18, 2010, subject to the terms and conditions of the Purchase Agreement between Electromed and Feltl and Company, Inc., who is acting as the underwriter for the offering. In addition, the underwriter has a 45-day option to purchase up to an additional 255,000 shares of common stock to cover over-allotments, if any.

Electromed's common stock will be listed on the Nasdaq Capital Market and will trade under the symbol "ELMD."

The offering is being made solely by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained, when available, from Feltl and Company, Inc. at 2100 LaSalle Plaza, 800 LaSalle Avenue, Minneapolis MN 55402, (612) 492-8800. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 12, 2010.

Source:

Electromed, Inc.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.